SCHEDULE 13G/A: Anson Funds Group Discloses 1.4% Passive Stake in Bluejay Diagnostics

Anson Funds Management LP and affiliated entities have filed an Amendment No. 1 to Schedule 13G, disclosing a 1.4% beneficial ownership stake in Bluejay Diagnostics, Inc. as of December 31, 2024.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing pertains to their beneficial ownership of Common Stock, $0.0001 par value, of Bluejay Diagnostics, Inc. (the "Issuer").
• As of December 31, 2024, the Reporting Persons collectively beneficially own 367,950 shares of Common Stock.
• This represents 1.4% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 26,883,971 shares issued and outstanding (as reported in the Issuer's Form 10-Q on November 7, 2024) plus 367,950 shares receivable upon exercise of warrants held by the Fund.
• The shares are held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors.
• The Reporting Persons have shared voting and shared dispositive power over these 367,950 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, with no positive or negative implications for the issuer's performance or outlook. It simply updates a passive investment stake.

Risks

• The document does not explicitly detail risks for the issuer, but rather certifies that the reporting persons' stake is passive and not intended to influence control, mitigating potential risks associated with activist investors.

Future Outlook

The document, a Schedule 13G amendment, does not provide any forward-looking statements or guidance regarding Bluejay Diagnostics, Inc.'s future operations or financial performance.

Management Comments

• The Reporting Persons certify that, to the best of their knowledge and belief, the securities were acquired and held in the ordinary course of business and were not acquired and were not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

This filing is a routine disclosure of a passive investment stake by an investment group in a diagnostics company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, albeit passive, ownership stake by an investment group, confirming that the shares are held for investment purposes rather than control.

Key Dates

Keywords

Bluejay Diagnostics, Anson Funds Management LP, Anson Advisors Inc., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Advisors, Passive Investment